Blocking Wnt signaling by SFRP-like molecules inhibits in vivo cell proliferation and tumor growth in cells carrying active Β-catenin

Oncogene

Volumn 30, Issue 4, 2011, Pages 423-433

  Lavergne, E ^a,b   Hendaoui, I ^a,b   Coulouarn, C ^a,b   Ribault, C ^a,b   Leseur, J ^a,b,c   Eliat, P A ^b,d   Mebarki, S ^a,b   Corlu, A ^a,b   Clement B ^a,b   Musso, O ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c Centre Régional de Lutte Contre le Cancer   (France)

^d IFR 140   (France)

Author keywords

b catenin; collagen XVIII; colorectal cancer; frizzled; secreted frizzled related proteins; Wnt

Indexed keywords

BETA CATENIN; BROXURIDINE; GLYCOPROTEIN; SECRETED FRIZZLED RELATED PROTEIN 1; THYMIDINE; UNCLASSIFIED DRUG; V3NTER; WNT PROTEIN;

ALLELE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CLONOGENESIS; COLON CANCER; COLON POLYPOSIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; BETA CATENIN; CELL PROLIFERATION; COLORECTAL NEOPLASMS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; GLYCOPROTEINS; HCT116 CELLS; HUMANS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; SIGNAL TRANSDUCTION; WNT PROTEINS;

MUS;

EID: 79251634676     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.432     Document Type: Article

References (53)

1. Ahmed N, Oliva K, Wang Y, Quinn M, Rice G. (2003). Proteomic profiling of proteins associated with urokinase plasminogen activator receptor in a colon cancer cell line using an antisense approach. Proteomics 3: 288-298.
2. Albihn A, Johnsen JI, Henriksson MA. (2010). MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res 107: 163-224.
3. Bafico A, Liu G, Goldin L, Harris V, Aaronson SA. (2004). An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell 6: 497-506.
4. Barker N, Clevers H. (2006). Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 5: 997-1014.
5. Bovolenta P, Esteve P, Ruiz JM, Cisneros E, Lopez-Rios J. (2008). Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. J Cell Sci 121: 737-746.
6. Caldwell GM, Jones C, Gensberg K, Jan S, Hardy RG, Byrd P et al. (2004). The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res 64: 883-888.
7. Chan TA, Wang Z, Dang LH, Vogelstein B, Kinzler KW. (2002). Targeted inactivation of CTNNB1 reveals unexpected effects of beta-catenin mutation. Proc Natl Acad Sci USA 99: 8265-8270.
8. Chitalia VC, Foy RL, Bachschmid MM, Zeng L, Panchenko MV, Zhou MI et al. (2008). Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL. Nat Cell Biol 10: 1208-1216.
9. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. (2009). Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 28: 3526-3536.
10. Dann CE, Hsieh JC, Rattner A, Sharma D, Nathans J, Leahy DJ. (2001). Insights into Wnt binding and signalling from the structures of two Frizzled cysteine-rich domains. Nature 412: 86-90.
11. de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O et al. (1998). Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 95: 8847-8851.
12. DeAlmeida VI, Miao L, Ernst JA, Koeppen H, Polakis P, Rubinfeld B. (2007). The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo. Cancer Res 67: 5371-5379.
13. Dimitriadis A, Vincan E, Mohammed IM, Roczo N, Phillips WA, Baindur-Hudson S. (2001). Expression of Wnt genes in human colon cancers. Cancer Lett 166: 185-191.
14. Dimitrova YN, Li J, Lee YT, Rios-Esteves J, Friedman DB, Choi HJ et al. (2010). Direct ubiquitination of beta-catenin by Siah-1 and regulation by the exchange factor TBL1. J Biol Chem 285: 13507-13516.
15. Elamaa H, Peterson J, Pihlajaniemi T, Destree O. (2002). Cloning of three variants of type XVIII collagen and their expression patterns during Xenopus laevis development. Mech Dev 114: 109-113.
16. Elamaa H, Snellman A, Rehn M, Autio-Harmainen H, Pihlajaniemi T. (2003). Characterization of the human type XVIII collagen gene and proteolytic processing and tissue location of the variant containing a frizzled motif. Matrix Biol 22: 427-442.
17. Hart M, Concordet JP, Lassot I, Albert I, del los Santos R, Durand H et al. (1999). The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol 9: 207-210.
18. He B, Reguart N, You L, Mazieres J, Xu Z, Lee AY et al. (2005). Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene 24: 3054-3058.
19. Holcombe RF, Marsh JL, Waterman ML, Lin F, Milovanovic T, Truong T. (2002). Expression of Wnt ligands and Frizzled receptors in colonic mucosa and in colon carcinoma. Mol Pathol 55: 220-226.
20. Hu J, Dong A, Fernandez-Ruiz V, Shan J, Kawa M, Martinez-Anso E et al. (2009). Blockade of Wnt signaling inhibits angiogenesis and tumor growth in hepatocellular carcinoma. Cancer Res 69: 6951-6959.
21. Kawano Y, Kypta R. (2003). Secreted antagonists of the Wnt signalling pathway. J Cell Sci 116: 2627-2634.
22. Kenny PA, Enver T, Ashworth A. (2005). Receptor and secreted targets of Wnt-1/beta-catenin signalling in mouse mammary epithelial cells. BMC Cancer 5: 3.
23. Kolligs FT, Hu G, Dang CV, Fearon ER. (1999). Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression. Mol Cell Biol 19: 5696-5706.
24. Kyle AH, Huxham LA, Baker JH, Burston HE, Minchinton AI. (2003). Tumor distribution of bromodeoxyuridine-labeled cells is strongly dose dependent. Cancer Res 63: 5707-5711.
25. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y et al. (2002). Control of beta-catenin phosphorylation/degradation by a dualkinase mechanism. Cell 108: 837-847.
26. MacDonald BT, Tamai K, He X. (2009). Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17: 9-26.
27. Mikels AJ, Nusse R. (2006). Wnts as ligands: processing, secretion and reception. Oncogene 25: 7461-7468.
28. Mita AC, Mita MM, Nawrocki ST, Giles FJ. (2008). Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 14: 5000-5005.
29. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B et al. (1997). Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275: 1787-1790.
30. Munz M, Baeuerle PA, Gires O. (2009). The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 69: 5627-5629.
31. Muragaki Y, Timmons S, Griffith CM, Oh SP, Fadel B, Quertermous T et al. (1995). Mouse Col18a1 is expressed in a tissue-specific manner as three alternative variants and is localized in basement membrane zones. Proc Natl Acad Sci USA 92: 8763-8767.
32. Musso O, Theret N, Heljasvaara R, Rehn M, Turlin B, Campion JP et al. (2001). Tumor hepatocytes and basement membrane-producing cells specifically express two different forms of the endostatin precursor, collagen XVIII, in human liver cancers. Hepatology 33: 868-876.
33. Polakis P. (2007). The many ways of Wnt in cancer. Curr Opin Genet Dev 17: 45-51.
34. Quelard D, Lavergne E, Hendaoui I, Elamaa H, Tiirola U, Heljasvaara R et al. (2008). A cryptic frizzled module in cell surface collagen 18 inhibits Wnt/beta-catenin signaling. PLoS ONE 3: e1878.
35. Ramanujan S, Koenig GC, Padera TP, Stoll BR, Jain RK. (2000). Local imbalance of proangiogenic and antiangiogenic factors: a potential mechanism of focal necrosis and dormancy in tumors. Cancer Res 60: 1442-1448.
36. Rehn M, Hintikka E, Pihlajaniemi T. (1996). Characterization of the mouse gene for the alpha 1 chain of type XVIII collagen (Col18a1) reveals that the three variant N-terminal polypeptide forms are transcribed from two widely separated promoters. Genomics 32: 436-446.
37. Saarela J, Rehn M, Oikarinen A, Autio-Harmainen H, Pihlajaniemi T. (1998). The short and long forms of type XVIII collagen show clear tissue specificities in their expression and location in basement membrane zones in humans. Am J Pathol 153: 611-626.
38. Salahshor S, Woodgett JR. (2005). The links between axin and carcinogenesis. J Clin Pathol 58: 225-236.
39. Sansom OJ, Reed KR, Hayes AJ, Ireland H, Brinkmann H, Newton IP et al. (2004). Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev 18: 1385-1390.
40. Sekine S, Shibata T, Sakamoto M, Hirohashi S. (2002). Target disruption of the mutant beta-catenin gene in colon cancer cell line HCT116: preservation of its malignant phenotype. Oncogene 21: 5906-5911.
41. Smith K, Bui TD, Poulsom R, Kaklamanis L, Williams G, Harris AL. (1999). Up-regulation of macrophage wnt gene expression in adenoma-carcinoma progression of human colorectal cancer. Br J Cancer 81: 496-502.
42. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545-15550.
43. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD et al. (2004). Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 36: 417-422.
44. Taketo MM. (2004). Shutting down Wnt signal-activated cancer. Nat Genet 36: 320-322.
45. Takeuchi T, Hisanaga M, Nagao M, Ikeda N, Fujii H, Koyama F et al. (2004). The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer. Clin Cancer Res 10: 5572-5579.
46. Tetsu O, McCormick F. (1999). Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426.
47. Tolwinski NS, Wieschaus E. (2004). Rethinking WNT signaling. Trends Genet 20: 177-181.
48. Topol L, Jiang X, Choi H, Garrett-Beal L, Carolan PJ, Yang Y. (2003). Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. J Cell Biol 162: 899-908.
49. Treanor D, Quirke P. (2007). Pathology of colorectal cancer. Clin Oncol (R Coll Radiol) 19: 769-776.
50. Ueno K, Hiura M, Suehiro Y, Hazama S, Hirata H, Oka M et al. (2008). Frizzled-7 as a potential therapeutic target in colorectal cancer. Neoplasia 10: 697-705.
51. Vider BZ, Zimber A, Chastre E, Prevot S, Gespach C, Estlein D et al. (1996). Evidence for the involvement of the Wnt 2 gene in human colorectal cancer. Oncogene 12: 153-158.
52. Wang Z, Vogelstein B, Kinzler KW. (2003). Phosphorylation of betacatenin at S33, S37, or T41 can occur in the absence of phosphorylation at T45 in colon cancer cells. Cancer Res 63: 5234-5235.
53. Yang J, Zhang W, Evans PM, Chen X, He X, Liu C. (2006). Adenomatous polyposis coli (APC) differentially regulates betacatenin phosphorylation and ubiquitination in colon cancer cells. J Biol Chem 281: 17751-17757.